Oruka Therapeutics (NASDAQ:ORKA) Reaches New 1-Year High – Should You Buy?

Oruka Therapeutics, Inc. (NASDAQ:ORKA) shares hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $36.53 and last traded at $35.5260, with a volume of 40860 shares changing hands. The stock had previously closed at $35.56.

Wall Street Analyst Weigh In

Several brokerages have weighed in on ORKA. BTIG Research increased their target price on shares of Oruka Therapeutics from $63.00 to $73.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. Wall Street Zen cut shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, November 16th. UBS Group began coverage on shares of Oruka Therapeutics in a report on Wednesday, January 7th. They issued a “buy” rating and a $50.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Thursday, January 22nd. Finally, Piper Sandler assumed coverage on Oruka Therapeutics in a report on Thursday, December 18th. They issued an “overweight” rating and a $75.00 price objective on the stock. Eight research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $54.50.

Oruka Therapeutics Stock Down 0.2%

The firm has a market cap of $1.66 billion, a PE ratio of -17.94 and a beta of -0.38. The business has a 50-day moving average price of $32.21 and a two-hundred day moving average price of $26.01.

Insider Transactions at Oruka Therapeutics

In other news, insider Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $32.37, for a total value of $226,590.00. Following the completion of the transaction, the insider owned 34,018 shares in the company, valued at approximately $1,101,162.66. This trade represents a 17.07% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last quarter, insiders sold 21,000 shares of company stock valued at $663,530. 24.69% of the stock is owned by company insiders.

Institutional Investors Weigh In On Oruka Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Legal & General Group Plc acquired a new position in Oruka Therapeutics in the second quarter valued at $28,000. Ameritas Investment Partners Inc. purchased a new position in Oruka Therapeutics during the 2nd quarter worth approximately $31,000. BNP Paribas Financial Markets increased its position in Oruka Therapeutics by 464.0% during the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock worth $31,000 after buying an additional 2,306 shares during the period. Royal Bank of Canada lifted its stake in Oruka Therapeutics by 47.2% in the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after buying an additional 365 shares during the last quarter. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of Oruka Therapeutics in the fourth quarter valued at approximately $37,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.